Explore the words cloud of the CoaguPOC project. It provides you a very rough idea of what is the project "CoaguPOC" about.
The following table provides information about the project.
Coordinator |
RELOGABLE S.L.
Organization address contact info |
Coordinator Country | Spain [ES] |
Project website | http://www.relogable.com/projects.html |
Total cost | 71˙429 € |
EC max contribution | 50˙000 € (70%) |
Programme |
1. H2020-EU.3.1.4. (Active ageing and self-management of health) 2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.1.6. (Health care provision and integrated care) |
Code Call | H2020-SMEINST-1-2016-2017 |
Funding Scheme | SME-1 |
Starting year | 2017 |
Duration (year-month-day) | from 2017-05-01 to 2017-08-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | RELOGABLE S.L. | ES (LAS ROZAS DE MADRID) | coordinator | 50˙000.00 |
The goal we seek in CoaguPOC project is to develop a “ready to the market” smart point-of-care device for self-patient management of the Oral Anticoagulant Therapy (OAT). OAT is a long-term or even chronic therapy necessary to inhibit the formation of potentially lethal blood clots in patients with high risk of thrombosis; e.g. strokes, the 2nd single largest cause of death in the world. Approximately 2% of the population are prescribed long-term oral anticoagulants, meaning that more than 10-12 million people are treated in Western Europe.
OAT therapy needs regular tests to confirm correct dosage levels because the drugs have a narrow therapeutic window and small changes in systemic changes can give rise to adverse toxic effects. Tests are usually made once a month in a nursing service at the hospital or care center. The constant increase on the number of anti-coagulant patients (around 10% annually) is highly intensifying pressure and cost on the healthcare resources required to monitor, prevent and manage adverse events.
The use of point-of-care coagulometers at home for self-monitoring may avoid unnecessary visits to hospitals or clinics while permitting more frequent monitoring and timely adjustment of anticoagulant dosing to avoid adverse events. The OAT self-management leads to important reductions on adverse events, as thrombosis (reduction by 50%), major hemorrhages (12%), death (18%) and thrombotic events (67%) as compared to ‘usual care‘. It also has a substantial impact on the quality of life of patients and their families, and important cost savings on the healthcare system. For instance, in UK a mere increase of 5% improved in average therapeutic range, led to a reduction of 550 strokes per year and associated cost saving of around €12,000 per patient.
CoaguPOC aims bringing to the market the first low-cost and smart point of care device for OAT patients to self-monitor and self-manage their chronic condition. We aim to bring the lab to your pocket
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COAGUPOC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "COAGUPOC" are provided by the European Opendata Portal: CORDIS opendata.
CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research
Read MoreSensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.
Read MoreBioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously
Read More